Although new T2DM therapies, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have demonstrated cardiovascular benefits (6, 7), it is still crucial to identify and manage T2DM patients who are at risk of developing MI at an early stage. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.